Yes i agree with Doctor on that.
We just need to remember that the company doesn't actually need any further money to see a majority of the pipeline into the market. This and the fact that they need to keep the products they are working on secret to help them be first in with the generic for the particular product is why we don't get many updates. It makes sense that a company that requires shareholder funds will usually pump up the company to ensure value at cap raising which we hopefully don't need to worry about with our current cash balance.
Lack of news is frustrating at times but the fact that the current cash should see us through to revune on low risk products that have "very healthy margins" is a major upside to the alternative high risk specialised product that could require endless investment from shareholders.
Im looking forward to the annual report next month where we should get a good view on the pipeline progress and cash burn.
Good luck all in my own opinion
Add to My Watchlist
What is My Watchlist?
